Summary

Cardiovascular Surgical Devices Market Trends & Summary

Cardiovascular Surgical Devices market is expected to reach US$ 2.86 billion by 2033 from US$ 2.11 billion in 2024, with a CAGR of 3.45% from 2025 to 2033. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The report Cardiovascular Surgical Devices Market & Forecast covers by Product Type (Beating Heart Surgery Systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposable), Application (Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Others), End-User (Hospitals, Ambulatory Surgical Centers, Others), Country and Company 2025-2033.


Cardiovascular Surgical Devices Industry Overview

The medical equipment and technologies used in the diagnosis, treatment, and management of heart-related illnesses, including arrhythmias, heart valve problems, and coronary artery disease, are the main focus of the cardiovascular surgical devices sector. Stents, heart valves, bypass grafts, pacemakers, defibrillators, and surgical tools are among the main goods. The growing incidence of cardiovascular diseases as a result of aging populations, sedentary lifestyles, and poor diets are some of the factors driving market expansion. Robotic-assisted operations and minimally invasive procedures are examples of technological advancements that have improved patient outcomes while cutting recovery times and medical expenses. Government funding, improvements in diagnostics, and growing healthcare awareness all support industry growth. High expenses, legal restrictions, and the demand for continuous clinical research to improve device efficacy and safety provide difficulties for the sector.

One of the most common illnesses in the world is cardiovascular disease. Cardiovascular disease (CVD) was the top cause of mortality in the United States in January 2024, accounting for 931,578 fatalities, more than all malignancies and chronic respiratory diseases combined, according to the American Heart Association. Cardiovascular devices are therefore essential for precisely identifying and treating heart conditions, which supports market growth. Rapid technological advancement, an increase in reasonably priced and efficient technologies, and growing demand for minimally invasive procedures are the primary factors propelling this market.

The market is expanding as a result of the rise in chronic cardiovascular disease cases. The need for cardiovascular devices has grown as a result of a rise in cardiovascular diseases. One of the most important cardiovascular devices is a heart or coronary artery stent. They make it easier to treat heart conditions such heart attacks, coronary disease, atrial fibrillation, and the growth of clogged arteries that are thought to pose a major risk to life. According to a WHO analysis from May 2024, cardiovascular diseases (CVDs) account for over 42.5% of all deaths in Europe each year, or almost 10,000 deaths per day, making them the leading cause of disability and early death. Men are over 2.5 times more likely than women to die from cardiovascular diseases (CVDs), and young people in Eastern Europe and Central Asia (ages 30-69) are at approximately five times the risk of dying from these diseases than their counterparts in Western Europe.


Growth Drivers for the Cardiovascular Surgical Devices Market

Increase in Cardiovascular Disease Prevalence

Plywood's In terms of expenses and medical services, the most common cause of patient growth is heart disease. One of the main factors driving the growth of the cardiovascular devices market is the increase in the prevalence of chronic cardiovascular illnesses like heart failure and coronary artery disease (CAD). Coronary or cardiac stents are among the most important cardiovascular devices. These devices aid in the treatment of potentially fatal cardiac problems, including atrial fibrillation, coronary heart disease, heart attacks, and constricted artery opening. The global need for sophisticated cardiac devices is increased by the frequency of cardiac disorders.

According to Centers for Disease Control and Prevention (CDC) data released in November 2023, 4.9% of adults in the United States received a coronary heart disease diagnosis in 2022. Additionally, cardiovascular illnesses account for 695,547 fatalities in 2022, making them the leading cause of death in the United States. The World Health Organization estimates that heart disease claims 17.9 million lives annually.

Furthermore, the market's expansion is significantly aided by the rise in regulatory bodies' approvals of innovative gadgets. The market will likely be guided over the forecast period by a number of efforts implemented by state bodies to make cardiovascular devices available to a broad population in developing regions.


Growing Accessibility of Effective Devices

The need for effective heart devices is fueled by the apparent rise in the prevalence of heart illnesses worldwide. The adoption of modern technology in these countries can be attributed to their accessibility. The market has also been stimulated by initiatives that have been implemented to meet the growing demand for these devices in emerging markets. Additionally, investors are concentrating on increasing the accessibility of affordable cardiovascular equipment in nations like China, Mexico, India, and others. In consequence, this is anticipated to draw a significant portion of the market for cardiovascular devices in the years to come.

For example, UltraLinQ Healthcare Solutions debuted a new cardiac monitoring solution at the Arab Health 2023 conference in January 2023. It has an end-to-end system that enables hospitals and specialty clinics to provide Holter services to patients who visit their clinics or who can be accessed remotely at home.


Rising Adoption of Minimally Invasive Techniques

One major factor propelling the market's expansion is the growing use of minimally invasive procedures in cardiovascular surgery. Compared to open operations, these techniques have a number of benefits, including the use of sophisticated imaging, robotic help, and fewer incisions. Patients gain from shorter recovery periods, less discomfort, a decreased chance of infection, and fewer complications. The need for sophisticated cardiovascular devices like stents, catheters, and robotic surgical instruments has surged as a result of patients' growing preference for minimally invasive operations. Furthermore, minimally invasive procedures are more appealing to patients and healthcare professionals since they enable faster hospital discharge, lower medical expenses, and shorter treatment durations overall. The market for cardiovascular surgical equipment is anticipated to grow even faster as a result of the trend toward minimally invasive cardiac procedures and ongoing technological advancements.


Challenges in the Cardiovascular Surgical Devices Market

High Cost of Devices

One major obstacle in the industry is the high cost of sophisticated cardiovascular equipment, such as pacemakers, stents, and robotic surgical instruments. The cost of these gadgets rises because they frequently need significant investment in manufacturing, research, and development. Their accessibility is restricted by this cost barrier, especially in areas with low and intermediate incomes where healthcare budgets are tight. Disparities in cardiovascular care may result from patients in certain areas not having access to the newest, most efficient medicines. Furthermore, even with better results, healthcare practitioners in these areas might find it difficult to defend the cost. Manufacturers, governments, and healthcare systems must investigate cost-effective substitutes, price-cutting tactics, and creative financing methods to increase access and make these technologies more generally accessible and reasonably priced.


Regulatory and Compliance Hurdles

The market for cardiovascular surgical devices is severely hampered by regulatory and compliance issues. New device approval is frequently a drawn-out procedure that necessitates comprehensive clinical trials to prove long-term results, safety, and effectiveness. Authorities like the FDA, EMA, or other national agencies have strict regulations that manufacturers must follow. These regulations differ depending on the region. These specifications may lengthen product launch schedules, postponing market entry and reducing potential profits. Development costs may also be raised by the price of carrying out clinical trials, obtaining required data, and satisfying regulatory requirements. These obstacles could hinder innovation, particularly for smaller businesses with fewer resources, and delay the adoption of ground-breaking innovations that could enhance cardiovascular care outcomes for patients.


Cardiac arrhythmia drives demand for devices like pacemakers and defibrillators

Cardiac arrhythmia is pivotal in the cardiovascular surgical devices market because of its prevalence and life-threatening implications. This spurs demand for modern solutions like pacemakers and catheter ablation structures. For instance, in 2024, Boston Scientific Corporation received FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System, offering a unique technique for treating drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.


United States Cardiovascular Surgical Devices Market

The high prevalence of cardiovascular diseases (CVDs), an aging population, and growing awareness of heart health are the main factors driving the United States' cardiovascular surgical devices industry, which is among the biggest and most developed in the world. Devices for arrhythmias, heart valve problems, and coronary artery disease, such as pacemakers, defibrillators, robotic surgical instruments, and stents, are important market segments. Technological developments that improve patient outcomes and shorten recovery times, such as bioresorbable devices and minimally invasive operations, are driving market expansion. The adoption of cutting-edge equipment is also made easier in the United States by its well-established healthcare infrastructure, government support, and high healthcare spending rate. High gadget costs, difficulties with regulations, and problems with reimbursement, however, continue to be commercial obstacles. The US continues to be a major force behind the development and marketing of cardiovascular devices worldwide.

An American Heart Association report from January 2024 states that around 2,552 fatalities in the United States are caused by CVD per day. Because of the substantial impact that CVD has on public health, there is an urgent need for efficient management and treatment options in the US market.

Abbott introduced the Abbott HeartMates program in October 2023 to help heart patients by allowing them to connect with others experiencing similar heart health concerns and share their stories. Professional football player Damar Hamlin served as the company's first ambassador at the beginning of the campaign under this program.


Germany Cardiovascular Surgical Devices Market

Due to its sophisticated healthcare system, elderly population, and high prevalence of cardiovascular diseases (CVDs), Germany is one of Europe's largest markets for cardiovascular surgical equipment. The adoption of sophisticated cardiovascular equipment, including as pacemakers, heart valves, stents, and surgical robots, is facilitated by the nation's robust reimbursement regulations and well-established medical infrastructure. Germany's emphasis on innovation, bolstered by a robust research and development environment, makes it easier to introduce innovative technology such as bioresorbable devices and minimally invasive procedures. The market is also growing as a result of the rising need for therapies for arrhythmias, heart failure, and coronary artery disease. Strict regulatory standards, the expensive cost of sophisticated gadgets, and rivalry from other European nations are some of the market's obstacles, nevertheless. Germany is nevertheless a major player in the global market for cardiovascular surgical devices in spite of these obstacles.

Data from a German registry for 2023, which included 168,841 cardiac and vascular surgeries in 77 institutions, was published in January 2024 by The Journal of Thoracic and Cardiovascular Surgery. The unadjusted in-hospital survival rates for 28,996 coronary artery bypass grafts, 39,859 cardiac valve surgeries, and 19,699 pacemaker/ICD implants were 97.6%, 97.7%, and 99.2%, respectively. In addition, 324 heart transplants and 2,982 extracorporeal life support treatments were carried out.


India Cardiovascular Surgical Devices Market

The increasing prevalence of cardiovascular diseases (CVDs) and improved access to healthcare are driving the market for cardiovascular surgical devices in India. Heart disease is becoming more prevalent in the nation as a result of aging populations, urbanization, and shifting lifestyles. Government programs, growing public awareness of heart health, and the development of healthcare infrastructure are important market drivers. Particularly in urban areas, there is a growing need for cardiovascular equipment such as heart valves, pacemakers, stents, and angioplasty instruments. Additionally, as doctors and patients look for better results and faster recovery periods, the use of minimally invasive procedures is increasing. However, obstacles including exorbitant equipment expenses, restricted reimbursement, and restricted availability in remote regions may prevent the industry from growing further. India continues to be a promising market for producers of cardiovascular devices in spite of these obstacles.

In the Indian state of Maharashtra, a decrease in the cost of coronary stents resulted in a 43.0% rise in the number of heart procedures performed, according a study conducted by the Harvard T.H. Chan School of Public Health (HSPH).


Saudi Arabia Cardiovascular Surgical Devices Market

Due to the high prevalence of cardiovascular diseases (CVDs) and significant healthcare investments, the market for cardiovascular surgical equipment is growing quickly in Saudi Arabia. An aging population, sedentary lifestyles, and changing lifestyles are the main causes of the Kingdom's rising heart disease rates. The government's Vision 2030 program, which aims to improve medical technology, expand access to high-quality care, and strengthen healthcare infrastructure, is driving up demand for sophisticated cardiovascular devices like heart valves, pacemakers, defibrillators, and stents. Furthermore, the industry is expanding more quickly due to consumers' increasing preference for minimally invasive procedures. Widespread adoption may be hampered by issues including exorbitant device costs, a lack of local manufacturing, and the requirement for specialized training for sophisticated treatments. Saudi Arabia is still a major Middle Eastern market for cardiovascular surgical devices in spite of this.

The BMC Cardiovascular Diseases article from March 2024 states that 1.6% of Saudi Arabians aged 15 and older had cardiovascular disease. This statistic shows the proportion of people in this age group who suffer from heart disease and other cardiovascular diseases of various kinds. The information highlights an important facet of the nation's health profile and sheds light on the prevalence of cardiovascular diseases among Saudi Arabians.


Cardiovascular Surgical Devices Market Segments

Product Type – Market breakup in 4 viewpoints:
1. Beating Heart Surgery Systems
2. Cardiopulmonary Bypass Equipment
3. Cardiac Ablation Devices
4. Perfusion Disposable


Application – Market breakup in 5 viewpoints:
1. Congenital Heart Defects
2. Cardiac Arrhythmia
3. Coronary Heart Disease
4. Congestive Heart Failure
5. Others


End-User – Market breakup in 3 viewpoints:
1. Hospitals
2. Ambulatory Surgical Centers
3. Others


Country – Market of 25 Countries Covered in the Report:
1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. Abbott Laboratories
2. Boston Scientific Corporation
3. Edwards Lifesciences
4. Cardinal Health Inc.
5. Medtronic PLC
6. GE Healthcare
7. LivaNova PLC
8. Terumo Corporation


Key Questions Answered in Report:
1. How big is the Cardiovascular Surgical Devices industry?
The global Cardiovascular Surgical Devices market size was valued at US$ 2.11 billion in 2024 and is expected to reach US$ 2.86 billion in 2033.

2. What is the Cardiovascular Surgical Devices growth rate?
The global Cardiovascular Surgical Devices market is expected to expand at a compound annual growth rate (CAGR) of 3.45% from 2025 to 2033.

3. Who are the key players in Cardiovascular Surgical Devices industry?
Some key players operating in the Cardiovascular Surgical Devices market includes Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, GE Healthcare, LivaNova PLC, and Terumo Corporation.

4. What are the factors driving the Cardiovascular Surgical Devices industry?
Ageing populations, rising rates of heart disease, technological developments, minimally invasive procedures, government funding for healthcare, increased public awareness of healthcare issues, and the need for better patient outcomes and surgical efficiency are all factors driving the cardiovascular surgical devices market.

5. Which Region held the largest market share in the Cardiovascular Surgical Devices industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Cardiovascular Surgical Devices Market report?
Product Type, Application, End User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Cardiovascular Surgical Devices Market


6. Market Share
6.1 By Product Type
6.2 By Application
6.3 By End User
6.4 By Countries


7. Product Type
7.1 Beating Heart Surgery Systems
7.2 Cardiopulmonary Bypass Equipment
7.3 Cardiac Ablation Devices
7.4 Perfusion Disposable


8. Application
8.1 Congential Heart Defects
8.2 Cardiac Arrthymia
8.3 Coronary Heart Disease
8.4 Congestive Heart Failure
8.5 Others


9. End User
9.1 Hospitals
9.2 Ambulatory Surgical Centers
9.3 Others


10. Countries
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherland
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Key Players Analysis
13.1 Abbott Laboratories
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue Analysis

13.2 Boston Scientific Corporation
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue Analysis

13.3 Edwards Lifesciences
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue Analysis

13.4 Cardinal Health Inc.
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue Analysis

13.5 Medtronic PLC
13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue Analysis

13.6 GE Healthcare
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue Analysis

13.7 LivaNova PLC
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue Analysis

13.8 Terumo Corporation
13.8.1 Overview
13.8.2 Recent Development
13.8.3 Revenue Analysis